Subscribe To

Price Alert Latest News Economic Calendar News

ABCL / AbCellera Biologics Inc. (ABCL) CEO Dr. Carl Hansen on Q2 2022 Results - Earnings Call Transcript

AbCellera Biologics Inc. (NASDAQ:ABCL ) Q2 2022 Earnings Conference Call August 9, 2022 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Dr. Carl Hansen - President and CEO Andrew Booth - CFO Conference Call Participants Tiago Fauth - Credit Suisse Puneet Souda - SVB Securities Stephen Willey - Stifel Gary Nachman - BMO Capital Markets Do Kim - Piper Sandler Antonia Borovina - Bloom Burton Operator Good afternoon and welcome to AbCellera Second Quarter 2022 Business Update and Conference Call. My name is Libya and I'll facilitate the audio portion of today's indirect broadcast. Read More

Demo Live Account See Partner Details

Content Topics

Abcellera

Biologics

Inc

ABCL

Carl

Hansen

2022

Results

abcl

Earnings

Transcript

Stock

Posted: Aug 10 2022, 00:10

Author Name: Seeking Alpha

ABCL News

By Seeking Alpha
November 2, 2023

AbCellera Biologics Inc. (ABCL) Q3 2023 Earnings Call Transcript

AbCellera Biologics Inc. (NASDAQ:ABCL ) Q3 2023 Results Conference Call November 2, 2023 5:00 PM ET Company Participants Tryn Stimart - Chief Legal &

By Zacks Investment Research
October 26, 2023

New Strong Buy Stocks for October 26th

GRPN, NRIX, RNLX, ABCL and SMAR have been added to the Zacks Rank #1 (Strong Buy) List on October 26, 2023.

By Business Wire
October 11, 2023

AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023.

By InvestorPlace
August 8, 2023

3 AI Stocks You'll Regret Not Buying Soon

Artificial intelligence ( AI ) will have a profound impact on the medical industry, where it could help accelerate drug discovery and patient treatmen

By Seeking Alpha
August 3, 2023

AbCellera Biologics Inc. (ABCL) Q2 2023 Earnings Call Transcript

AbCellera Biologics Inc. (NASDAQ:ABCL ) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Tryn Stimart - Chief Legal & C

By Zacks Investment Research
July 25, 2023

Does AbCellera Biologics Inc. (ABCL) Have the Potential to Rally 242.09% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 242.1% in AbCellera Biologics Inc. (ABCL). While the effectiv

By InvestorPlace
July 8, 2023

Looking for Biotech AI Stocks? 3 Names That Will Benefit From the AI Boom

AI is coming to biotech in a big way. From protein folding to drug screening, from studying cells to studying populations, the AI boom has long been a

By Business Wire
May 29, 2023

AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13,

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.